Safety of the blood supply in Mexico from 1999 to 2003

Centro Nacional de la Transfusión Sanguínea.
Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion (Impact Factor: 0.48). 03/2006; 58(2):101-8.
Source: PubMed


The incidence of the infection by the viruses of the human immunodeficiency (HIV), hepatitis B (HBV) and hepatitis C (HCV) has diminished enormously in developed countries during the last 20 years; nevertheless, in our country we do not know such an incidence and, therefore, the safety of our blood supply.
We performed a retrospective analysis at the Centro Nacional de la Transfusión Sanguínea (CNTS) assessing 17,176,298 serologic tests including HIV, HCV and HBV carried on 5,725,432 blood units collected and informed to the CNTS from January 1999 to December 2003 by all the Mexican blood banks. Prevalence, incidence and residual risk of each one of the aforementioned serologic markers were calculated.
The five years mean prevalence for HIV, HBV and HCV has remained steady. The residual risk (RR) when hemagglutination test was employed was 1:977 for HCV; 1:1,564 for HBV and 1:1,262 for HIV. Whereas the RR when ELISA was performed decreased to 1:2,781 for HCV; 1:3,185 for HBV and 1:9,969 for HIV. If nucleic acid amplification test were employed, RR would be 1:8,170 for HBV; 1:9,915 for HCV and 1:19,939 for HIV.
The theoretical risk for transfusion-transmitted diseases in our country is still worrisome.

4 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: To determine the prevalence of serological markers for the human immunodeficiency virus (HIV), hepatitis B (HVB) and C (HCV) viruses, and Treponema pallidum in blood donors. The results of the screening tests from blood donors studied at the Central Blood Bank of the Ignacio Garcia Tellez National Medical Center, in Merida, Yucatan, Mexico between January 2002 and December 2004, have been retrospectively evaluated. Of 39,933 blood donors, 424 (1.06%) were positive to one or more serological markers. The seropositivity rates for anti-HIV, HBsAg, anti-HCV and anti-Treponema pallidum were found as 0.13%, 0.20%, 0.44% and 0.29%, respectively. Western Blot positive was found in 41 (77.36%) of the 53 blood donors positive for anti-HIV. In this study, the prevalence of serological markers was similar or lower than that reported in previous studies in Mexico.
    Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion 11/2006; 58(6):567-72. · 0.48 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Chronic hepatitis C (CHC) is the second cause of endstage liver disease in our country and one of the main indications of liver transplantation. Hepatitis C virus (HCV) genotype is the principal prognostic factor and the determinant of the therapeutic scheme. In our country few data exist regarding the prevalence of HCV infection and genotype distribution in the Mexican Republic has not been determined. The aim of this study was to characterize the prevalence of the different HCV genotypes and to explore their geographical distribution. Mexican patients with hepatitis C infection, detected throughout the country between 2003 and 2006, were included. All samples were analyzed by a central laboratory and Hepatitis C genotype was identified by Line Immuno Probe Assay in PCR positive samples (Versant Line Probe Assay Quest Diagnostics Nichols Institute, San Juan Capistrano CA). Data were analyzed according to the four geographical areas in Mexico. One thousand three hundred and ninety CHC patients were included. The most frequent genotype detected was genotype 1 (69%) followed by genotype 2 (21.4%) and genotype 3 (9.2%). Genotype 4 and 5 were infrequent. There was no subject infected with genotype 6. Genotype 1 and 2 exhibit very similar distribution in all geographical areas. Genotype 3 infected patients were more frequent in the North region (52%) compared with other areas:center-western (30%), center (17%), South-South east (1%) (p < 0.001). The most prevalent HCV genotype in Mexico is genotype 1. Geographical distribution of HCV genotypes in the four geographical areas in Mexico is not homogenous with a greater frequency of genotype3 in the north region. This difference could be related to the global changes of risk factors for HCV infection.
    Annals of hepatology: official journal of the Mexican Association of Hepatology 07/2007; 6(3):156-60. · 2.07 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: OBJECTIVE: UNAIDS has recognized that estimating HIV infection at a national or regional level is important for evaluation, program planning and advocacy. Following this recommendation, the purpose of this study was to estimate the magnitude of HIV infection prevalence among adults from the general population using information from the National Health Survey (ENSA 2000), a probabilistic, multi-stage, stratified, cluster household survey conducted by the Mexican Ministry of Health between November 1999 and June 2000. Availability of information from the Seroepidemiological Survey conducted in 1987 allowed for the estimation of trends between the two surveys (1987-2000). MATERIAL AND METHODS: A total of 21 271 males and females 20 years or older included in the ENSA 2000 were randomly selected and studied for anti-HIV 1/2 IgG (ELISA), confirmed by immunoelectrotransference (WB), and for risk factors associated with HIV infection. Samples were processed in the National Institute of Public Health in 2005. RESULTS: Prevalence for HIV infection was 0.25%. The main factors associated with infection were younger ages, male gender, residence in the Federal District, college education or higher, and being single or divorced. CONCLUSIONS: Seroprevalence among adults shows a ten-fold increase as compared with the results of the national seroprevalence survey of 1987. Although the epidemic continues to be concentrated among men who have sex with men, results provide evidence of dissemination towards the heterosexual population.
    Salud publica de Mexico 01/2007; 49:s386-94. · 0.94 Impact Factor
Show more